Cortex's CEO to Speak at Annual UBS Warburg Global Life Sciences Conference on September 22, 2003.Business Editors/Health/Medical Writers IRVINE, Calif.--(BUSINESS WIRE)--Sept. 8, 2003 Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR) announced that Roger G. Stoll, Ph.D., Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cortex Pharmaceuticals, Inc., will speak at the 5th Annual UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg Global Life Sciences Conference on Monday, September 22nd at 2:30 PM (EST EST electroshock therapy. EST abbr. electroshock therapy ). The conference will be held at The Plaza Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. in New York from September 22-25, 2003. Cortex Pharmaceuticals has pioneered a new class of medicine called AMPAKINE(R) compounds, which enhance memory and cognition by acting on chemical pathways that impact at least 85% of all the neurotransmission occurring in the brain. Dr. Stoll will discuss Cortex's AMPAKINE drug development platform, an update on the Company's new business model, the status of the Company's clinical programs, additional applications for these drugs and current activities with Cortex's corporate partners. A live audio webcast of the presentation will also be available on the UBS website at http://www.ibb.ubs.com/. An audio replay of the presentation will begin 3 hours after the presentation time and will be available until October 25, 2003. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act on the AMPA receptors on neurons to increase the strength of signals at connections between these brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in various neurological and psychiatric diseases. The AMPAKINE compounds are currently being evaluated in clinical trials for treatment of Alzheimer's disease, Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , schizophrenia, fragile X syndrome Fragile X Syndrome Definition Fragile X syndrome is the most common form of inherited mental retardation. Individuals with this condition have developmental delay, variable levels of mental retardation, and behavioral and emotional difficulties. , autism autism (ô`tĭzəm), developmental disability resulting from a neurological disorder that affects the normal functioning of the brain. It is characterized by the abnormal development of communication skills, social skills, and reasoning. and sleep deprivation effects. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) Forward Looking Statement: Note -- This press release contains forward-looking statements concerning the Company's research and development activities, clinical trials and business development plans. Actual results may differ materially, depending on a number of risk factors, including the risks that the Company may be unable to obtain additional capital needed to continue its operations; that the agreements with Organon and Servier will not result in any commercial products or that any additional milestone payments will be earned by the Company; that the Company may be unable to arrive at additional corporate partnerships with other pharmaceutical companies on acceptable terms and therefore be required to independently fund clinical development of AMPAKINE compounds through the sale of additional equity securities or otherwise; that the Company's proposed products may at any time be found to be unsafe or ineffective for any or all of their proposed indications; that competitors may challenge or design around the Company's patents or develop competing technologies; and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not yet been shown to have efficacy in the treatment of any disease. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion